Tokyo, Japan, Apr. 03, 2006 - (JCN Newswire) - Astellas Pharma Inc.(TSE: 4503) announced that Astellas today established a new active pharmaceutical ingredient (API) manufacturing subsidiary “Astellas Pharma Chemicals Co., Ltd.” through a company split.
Astellas separated its Takahagi Plant, the manufacturing and analytical function for APIs for investigational use at the Process Chemistry Labs. and the site management function of the Bulk Technology Administration and transferd to Astellas Pharma Chemicals Co., Ltd.
The new subsidiary has through function for the production of APIs for investigational use and finished products and will contribute to the timely and accurate supply of APIs for investigational use, early establishment of new product production, the stable supply of products and the improvement of API manufacturing technology of the Astellas group.
The details of the new subsidiary are as follows:
Company name: Astellas Pharma Chemicals Co., Ltd. Location: 160-2, Akahama, Takahagi city, Ibaraki Prefecture Representative: Motoyoshi Katano, President Capital: 100 million yen Number of employees: about 100 Establishment: April 3, 2006 Business: Production and marketing of drugs and other products
About Astellas Pharma Inc. Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In April 2005, the company was formed through the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. The organization is committed to becoming a global mega pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information on Astellas Pharma Inc., please visit the company’s website at www.astellas.com.
Contact
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com
